Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.
ResMed Inc (ASX: RMD) is a United States based business that develops and manufactures medical devices to help people with sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed, which is short for Respiratory Medicine, was founded in 1989 by Dr Peter Farrell and now helps customers & patients in over 120 countries.
The S&P/ASX 200 (INDEXASX: XJO) closed 19.2 points, or 0.3%, higher at 6,997 and the broader All Ordinaries (INDEXASX: XAO) index was 0.2% higher, up 17.2 points at 7,192.3.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished up +0.28% to 6997.40.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished up +0.79% to 6772.90.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished up +0.21% to 6826.90.
After plenty of volatility for the ResMed Inc (ASX:RMD) share price, the healthcare company has released its FY24 first quarter update.
Here are 3 things I wish I knew about life and business at 23. For investors, this simply means: pessimism can work, from time to time. But over the long run — better on a brighter future is much, much, much better bet.
Will Ozempic sink ResMed Inc (ASX:RMD) and CSL Limited (ASX:CSL)? Will Tesla’s Cyber Truck come to Australia? The Australian Investors Podcast explains…
The local share market snapped its losing streak, with both the All Ordinaries (INDEXASX: XAO) and S&P/ASX200 (INDEXASX: XJO) gaining 0.4% on a settling of bond yields and the latest Reserve Bank meeting minutes.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished up +0.037% to 7091.00.